Jennifer Doudna on the Brave New World Being Ushered In by Gene Editing
CRISPR technology offers transformative potential for medicine and agriculture but raises significant ethical and societal concerns.
From cloning to CRISPR: The center that created Dolly designs epidemic-resistant animals
Roslin Institute has shifted focus from cloning to CRISPR gene editing to enhance animal disease resistance and improve livestock health.
Why Jennifer Doudna is one of Fast Company's 10 most innovative people of the last 10 years
CRISPR technology has revolutionized gene editing in medicine, impacting various diseases and treatment methodologies.
Controversial scientist says he'll use gene editing to end HIV & Alzheimer's
Controversial Chinese scientist He Jiankui faces consequences for gene-editing experiments on twins.
Despite criticism, He now aims to use 'base editing' to prevent Alzheimer's disease, setting the stage for potential breakthroughs in curing other diseases.
Mike Curtis
eGenesis is using CRISPR to edit pig genes for safer human organ transplants.
New AI can CHANGE human genes to cure even the rarest of diseases
AI-designed gene editing system OpenCRISPR-1 reduces off-target editing by 95%, offering potential for precise genetic disease cures.
Jennifer Doudna on the Brave New World Being Ushered In by Gene Editing
CRISPR technology offers transformative potential for medicine and agriculture but raises significant ethical and societal concerns.
From cloning to CRISPR: The center that created Dolly designs epidemic-resistant animals
Roslin Institute has shifted focus from cloning to CRISPR gene editing to enhance animal disease resistance and improve livestock health.
Why Jennifer Doudna is one of Fast Company's 10 most innovative people of the last 10 years
CRISPR technology has revolutionized gene editing in medicine, impacting various diseases and treatment methodologies.
Controversial scientist says he'll use gene editing to end HIV & Alzheimer's
Controversial Chinese scientist He Jiankui faces consequences for gene-editing experiments on twins.
Despite criticism, He now aims to use 'base editing' to prevent Alzheimer's disease, setting the stage for potential breakthroughs in curing other diseases.
Mike Curtis
eGenesis is using CRISPR to edit pig genes for safer human organ transplants.
New AI can CHANGE human genes to cure even the rarest of diseases
AI-designed gene editing system OpenCRISPR-1 reduces off-target editing by 95%, offering potential for precise genetic disease cures.
CRISPR-Cas9 gene editing restored vision in people with rare inherited blindness, improving sight without serious side effects.
Health Canada issues final decision, clearing regulatory pathway for gene-edited crops
Gene-edited crops in Canada now considered non-novel, treated like traditional breeds.
AI & robotics briefing: What running robots tell us about gaits
AI is used to design new gene-editing tools like CRISPR proteins, expanding capabilities beyond natural systems.
Researchers have adapted deep learning transformers for quantum computers, showing potential accuracy benefits over classical models.
Nobel laureates call on EU to relax rules on genetic modification
34 Nobel prize winners are urging the EU to relax rules on genetic modification before a key vote on gene editing.
They argue that gene editing techniques could make crops more resistant to disease and extreme weather events caused by climate change.
A Gene-Edited Pig Liver Was Attached to a Person-and Worked for 3 Days
Scientists used gene editing to make 69 genetic edits to a pig, including knocking out three pig genes and inserting seven human genes.
Previous attempts with unmodified pig livers failed within hours, but the pig livers with genetic edits in the Penn study showed stable blood flow and no signs of inflammation.
FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease
The US has approved the world's first medicine using Crispr technology.
Crispr technology has the potential to treat genetic conditions that are difficult to treat.
FDA approves first gene-editing treatments for human illness
The FDA has approved the first gene-editing treatments for sickle cell disease, marking a milestone in the field of gene-editing.
The treatments have the potential to provide more targeted and effective treatments for rare diseases with limited current options.
F.D.A. Approves Sickle Cell Treatments, Including One That Uses CRISPR
The Food and Drug Administration has approved the first gene editing therapy and conventional gene therapy for sickle cell disease.
Obstacles to treatment include limited access to authorized medical centers, individualized procedures, and high costs.
The CRISPR Era Is Here
Gene-editing technology CRISPR has successfully treated a patient with sickle-cell disease, providing hope for future treatments.
The treatment resulted in the patient living virtually symptom-free, with 29 out of 30 eligible patients experiencing zero pain crises after treatment.
The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to follow
U.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.
The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.
The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level.
UK authorizes first gene therapy for treating sickle cell disease
The UK's MHRA has approved the use of a gene-editing therapy for patients with sickle cell disease and beta thalassemia.
The therapy, called Casgevy, is the first-ever approved therapy that uses CRISPR-based gene editing technology.
The therapy has shown high efficacy in relieving severe pain associated with these blood disorders and could potentially replace the current standard of care.
Crispr gene editing shown to permanently lower high cholesterol
Researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol in a small test on people.
The gene-editing treatment aims to permanently lower cholesterol by using Crispr to edit a gene in the liver.
Preliminary results of the experiment were presented at the American Heart Association's annual meeting.
A Single Infusion of a Gene-Editing Treatment Lowered High Cholesterol
Researchers have shown that a single infusion of a gene-editing treatment can reduce cholesterol levels in people.
The treatment aims to permanently lower cholesterol by using Crispr to edit a gene in the liver, and initial results show significant reductions in LDL cholesterol.
Gene editing could provide a lasting option for treating hereditary high cholesterol, replacing the need for long-term medication.
Goodbye Statins? New Gene Editing Therapy Slashes High Cholesterol
A novel gene editing therapy using base editing lowered "bad" cholesterol levels in individuals with FH by as much as 55 percent.
The therapy could potentially provide a single-course treatment option for deep LDL lowering for decades without the need for daily pills or intermittent injections.
New Gene Editing Treatment Cuts Dangerous Cholesterol in Small Study
Gene editing treatment shows promise in lowering cholesterol levels in patients with severe heart disease
Treatment has the potential to transform preventive cardiology
The U.K. approved its first CRISPR gene-editing drugand the U.S. is expected to follow
U.K. regulators have approved the first-ever CRISPR gene-editing drug for the treatment of sickle cell disease and beta thalassemia.
The therapy has shown success in clinical trials and is expected to reach the U.S. by the end of the year.
The gene editing treatment modifies stem cells to boost the production of functional hemoglobin, providing a fix at the DNA level.
UK authorizes first gene therapy for treating sickle cell disease
The UK's MHRA has approved the use of a gene-editing therapy for patients with sickle cell disease and beta thalassemia.
The therapy, called Casgevy, is the first-ever approved therapy that uses CRISPR-based gene editing technology.
The therapy has shown high efficacy in relieving severe pain associated with these blood disorders and could potentially replace the current standard of care.
Crispr gene editing shown to permanently lower high cholesterol
Researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol in a small test on people.
The gene-editing treatment aims to permanently lower cholesterol by using Crispr to edit a gene in the liver.
Preliminary results of the experiment were presented at the American Heart Association's annual meeting.
A Single Infusion of a Gene-Editing Treatment Lowered High Cholesterol
Researchers have shown that a single infusion of a gene-editing treatment can reduce cholesterol levels in people.
The treatment aims to permanently lower cholesterol by using Crispr to edit a gene in the liver, and initial results show significant reductions in LDL cholesterol.
Gene editing could provide a lasting option for treating hereditary high cholesterol, replacing the need for long-term medication.
Goodbye Statins? New Gene Editing Therapy Slashes High Cholesterol
A novel gene editing therapy using base editing lowered "bad" cholesterol levels in individuals with FH by as much as 55 percent.
The therapy could potentially provide a single-course treatment option for deep LDL lowering for decades without the need for daily pills or intermittent injections.
New Gene Editing Treatment Cuts Dangerous Cholesterol in Small Study
Gene editing treatment shows promise in lowering cholesterol levels in patients with severe heart disease
Treatment has the potential to transform preventive cardiology
U.K. Is First to Approve a CRISPR-Based Therapy, Covering Two Blood Disorders
The UK has authorized a gene-editing medicine for treating sickle cell disease and beta thalassemia, marking the first approval worldwide for a therapy based on CRISPR technology.
The therapy, known as Casgevy, involves editing a gene in a patient's stem cells to produce high levels of fetal hemoglobin.
Casgevy offers a potentially curative treatment option for these inherited blood disorders, reducing the need for chronic therapies and blood transfusions.
Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approval
Regulators in Britain have approved the first treatment derived from CRISPR, called Casgevy, for sickle-cell disease and beta thalassemia.
About 2,000 patients in Britain are expected to be eligible for Casgevy treatment.
The FDA is expected to approve Casgevy for sickle-cell patients in the US in early December.
Researchers developed a gene-editing technology that reduces 'bad' cholesterol
A gene-editing treatment called VERVE-101 showed promising results in reducing cholesterol levels in patients with hereditary conditions.
The treatment used CRISPR editing techniques to turn off a cholesterol-raising gene in the liver, resulting in lower levels of LDL-C.
While the therapy has the potential to disrupt current high cholesterol treatments, further studies and FDA approval are needed before it can be widely available.
For the first time, gene-editing provides hints for lowering cholesterol
Preliminary results show that gene-editing can reduce high cholesterol levels in patients with a genetic condition.
More research is needed to confirm the safety and effectiveness of the treatment.
This could potentially provide a new way to prevent heart attacks and strokes.
IV infusion enables editing of the cystic fibrosis gene in lung stem cells
The development of gene editing techniques faces challenges in targeting specific cells and tissues affected by genetic diseases, requiring innovative approaches for effective treatment.